Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

As biotech turns 20...

Abstract

Biotechnology applied to pharmaceuticals has made significant contributions to medicine during the past 20 years. Although important products will continue to emerge, benefiting patients and perhaps lowering medical costs, there are too many biopharmaceutical companies chasing too few products, which are themselves over-regulated and incredibly expensive to test and bring to market.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Altman, L. US Unit backs human insulin for the market. New York Times 1 (October 30, 1982).

  2. 2

    Boston Consulting Group. The Contribution of Pharmaceutical Companies: What's at Stake for America (Boston Consulting Group, Boston, September 1993).

  3. 3

    Peck, C. C. Drug development: improving the process. Food Drug Law J. 52, 163–167 (1997).

    CAS  PubMed  Google Scholar 

  4. 4

    Tufts center for the Study of Drug Development. Outlook 2002 (Tufts Center for the Study of Drug Development, Boston, 2002).

  5. 5

    Miller, H. I. To America's Health: A Proposal to Reform the Food and Drug Administration (Hoover Institution Press, Stanford, California, 2000).

    Google Scholar 

  6. 6

    Shlaes, D. M. & Moellering, R. C. The US Food and Drug Administration and the end of antibiotics. Clin. Infect. Dis. 34, 420–423 (2002).

    Article  Google Scholar 

  7. 7

    Grabowski, H. G. & Vernon, J. M. The Regulation of Pharmaceuticals (American Enterprise Institute for Public Policy Research, Washington DC, 1983).

    Google Scholar 

  8. 8

    Zimm, A. Psoriasis drug delay sinks firms' shares. San Jose Mercury News C1 (April 6, 2002).

  9. 9

    Jaffe, S. Biotech–big pharma betrothals declining. The Scientist 57–58 (July 8, 2002).

  10. 10

    Anon. Global Pharmaceutical Company Partnering Capabilities Survey. PricewaterhouseCoopers [online] (cited 13 Aug 2002) <http://www.pwcglobal.com > (2000).

  11. 11

    Knight, J. Biotech woes set to hit academics. Nature 418, 5 (2002).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Related links

Related links

DATABASES

LocusLink

insulin

FURTHER INFORMATION

Biotechnology Industry Organization

NASDAQ Biotechnology Index

Tufts Center for the Study of Drug Development

US Department of Agriculture

US Food and Drug Administration

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Miller, H. As biotech turns 20.... Nat Rev Drug Discov 1, 1007–1008 (2002). https://doi.org/10.1038/nrd965

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing